Last reviewed · How we verify
NCT07075445
Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3
trial in Long QT Syndrome Type 3 in 200 participants. Currently enrolling.
1 December 2026
Quick facts
| Lead sponsor | Thryv Therapeutics, Inc. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 27 October 2025 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 December 2026 |
| Sites | 1 location across United States |
Conditions studied
- Long QT Syndrome Type 3 — all drugs for Long QT Syndrome Type 3 →
- Long QT Syndrome 2 — all drugs for Long QT Syndrome 2 →
Sponsor
Thryv Therapeutics, Inc. — full company profile →
Who can join
18 and older, any sex, with Long QT Syndrome Type 3 or Long QT Syndrome 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a cross-sectional observational study designed to assess the disease burden and quality of life in individuals with LQTS 2 and 3. Each participant will answer each patient-reported outcome questionnaire only once over a 6-month period. The study will enroll up to 200 participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07075445
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Thryv Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT07277582 — Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2) · Phase 2, PHASE3 · recruiting
- NCT07186946 — Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of TH · Phase 1 · completed
- NCT06507839 — Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268 · Phase 1 · completed
- NCT05906732 — Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Di · Phase 1, PHASE2 · terminated
- NCT05759962 — Phase 1 Study of LQT-1213 in Healthy Adults · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07075445 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Thryv Therapeutics, Inc.
- Last refreshed: 17 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07075445.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing